

Figure S1. Phylogenetic analysis of LRV *envelope* sequences and infectivity. (A) Phylogenetic analysis of Latent Reservoir Virus (LRV) *env* sequences (in color) from ten individuals and representative isolates from other clades rooted to HXB2 indicate all LRVs are subtype B. (B) An unrooted maximum-likelihood tree of the LRV *envelope* (*env*) sequences was constructed with 1916 filtered subtype B *env* sequences available on the Los Alamos National Laboratory database. LRV *env* sequences (in color as in (A)) positioned relatively to other subtype B sequences. Sequences from each participant clustered together and were distributed throughout the tree.




Figure S2. Infectivity of LRVs. Frequency of HIV gag p24 positive cells after 72 hours infection with LRVs from each of the ten chronically-infected individuals was measured using flow-cytometry based analysis. The graph represents the average of %p24+ cells \pm SD from 2 to 4 independent experiments.




Figure S3. ADCC activity against HIV-1 infected cells in the presence and absence of CD4 downregulation. ADCC activity of each antibody was tested using a primary *in vitro* autologous model, where P1095 LRV-infected primary CD4+T cells were used as targets and autologous purified and activated NK cells as effectors, with an E:T ratio of 5:1. The % specific killing is reported on the y-axis and the mAb dilution on the x-axis. Blue lines represent killing of CD4pos/p24pos cells, red lines represent killing of CD4neg/p24pos cells, and black line represents killing of CD4pos/p24neg cells. CH65 (an anti-influenza monoclonal antibody) was used as negative control. The results are the average of two replicates from a single experiment.

Table S1. Neutralization of WITO.IMC by individual mAbs.

		Neutralizing activity		
Antibody		IC ₅₀ , μg/ml	IC ₈₀ , μg/ml	
Non-HIV	CH65	>5	>5	
Non-neutralizing	A32	>5	>5	
	PG9	0.01	0.04	
	DH511.2_K3	1.55	>5	
	PGT121	>5	>5	
Neutralizing	CH557	0.89	2.30	
	PGT151	0.04	0.23	

³⁷ CH65 (an anti-influenza monoclonal antibody) was used as negative control.

Rank	Antibody combination	No.	ADCC	No of strains recognized
		Abs	score	(>20% killing)
1	A32+DH511.2K3+PGT121	3	4.36	9
2	All 6	6	4.24	10
2 3	A32+PGT151+DH511.2K3+PGT121	4	3.66	10
4	PGT151+PG9+DH511.2K3	3	3.62	9
5	A32+PG9+DH511.2K3	3	3	9
6	A32+CH557+DH511.2K3+PGT121	4	2.98	9
7	A32+PG9+CH557+DH511.2K3+PGT121	5	2.88	9
8	A32+CH557+PGT121	3	2.84	9
9	A32+PG9+DH511.2K3+PGT121	4	2.84	9
10	PGT151+PG9+CH557+DH511.2K3+PGT121	5	2.8	10
11	DH511.2K3+PGT121	2	2.52	9
12	A32+CH557+DH511.2K3	3	2.32	9
13	A32+PG9+PGT121	3	2.16	8
14	PG9+CH557+DH511.2K3+PGT121	4	2.12	9 9
15 16	A32+PGT151+PGT121	3 3	2.04 1.86	9
16 17	A32+PGT151+DH511.2K3 CH557+DH511.2K3+PGT121	3	1.52	9
18	PGT151+CH557+DH511.2K3+PGT121	4	1.48	10
19	A32+PG9+CH557	3	1.46	8
20	A32+PG9+CH557+PGT121	4	1.42	8
21	PGT151+PG9+CH557+DH511.2K3	4	1.34	8
22	A32+PGT151+PG9+CH557+DH511.2K3	5	1.26	8
23	A32+PG9+CH557+DH511.2K3	4	1.04	9
24	CH557+PGT121	2	1.02	8
25	A32+PGT151+CH557+DH511.2K3	4	0.84	9
26	A32+PGT151+PG9+CH557+PGT121	5	8.0	8
27	PGT151+PG9+DH511.2K3+PGT121	4	0.76	8
28	CH557+DH511.2K3	2	0.66	7
29	A32+PGT151+PG9+DH511.2K3	4	0.64	8
30	PGT151+PG9+CH557	3	0.62	5
31	A32+PGT151+CH557+PGT121	4	0.6	8
32	A32+PGT151+PG9	3	0.5	7
33	PG9+CH557+DH511.2K3	3	0.44	8
34	A32+PGT151+CH557	3	0.42	7
35	PGT151+DH511.2K3+PGT121	3	0.26	7
36	PGT151+PG9+CH557+PGT121	4	0.18	7
37	PGT151+PGT121	2	0.1	8
38	PG9+PGT121	2	0.04	7
39	A32+PGT151+PG9+PGT121	4	0	7
40	PGT151+DH511.2K3	2	-0.1	6
41	A32+PGT121	2 2	-0.32	6
43 44	PG9+CH557	2	-0.58	5 6
44	A32+DH511.2K3		-0.6	Ö

45	PG9+CH557+PGT121	3	-0.68	7
46	PG9+DH511.2K3	2	-0.8	6
47	A32+PGT151+PG9+CH557	4	-0.9	6
48	PGT151+CH557+PGT121	3	-1.38	6
49	PGT151+CH557+DH511.2K3	3	-2.08	6
50	PGT151+PG9+PGT121	3	-2.6	5
51	PGT151+PG9	2	-2.76	5
52	PGT121	1	-2.82	4
53	PGT151+CH577	2	-2.98	4
54	DH511.2K3	1	-3.04	3
55	A32+CH557	2	-3.78	2
56	CH65	1	-3.78	3
57	A32+PG9	2	-4.14	1
58	A32+PGT151	2	-4.2	2
59	CH557	1	-5.84	1
60	PG9	1	-6.46	0
61	PGT151	1	-6.76	0
62	A32	1	-7	0